Morgan Stanley Sees Growth Platforms Building for Stericycle

In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Stericycle SRCL. In the report, Morgan Stanley noted, “Organic revenue growth in 4Q13 ticked up slightly versus 3Q13 but remains consistent with 2012-13 trends. Greater traction from StrongPak is a modest positive but drove margin dilution. Full valuation and limited visibility on sustainable growth acceleration keeps us from a more constructive view.” Stericycle closed on Wednesday at $116.48.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsDavid R. LewisMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!